Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults
Maude St-Onge1, Kurt Anseeuw, Frank Lee Cantrell
11Centre antipoison du Québec, CHU de Quebec Research Center, Population Health and Optimal Health Practices, Department of Family Medicine and Emergency medicine, Department of Anesthesiology and Critical Care Medicine, Université Laval, Ville de Québec, Quebec, Canada. 2Department of Emergency Medicine, ZNA Stuivenberg, Antwerp, Belgium 3School of Pharmacy, University of California, San Francisco, San Francisco, CA. 4Heart and Vascular Institute, Penn State Hershey Medical Center, Hershey, PA. 5Department of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, Leuven, Belgium. 6Division of Emergency Medicine, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada. 7Department of Medical Biology, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, QC, Canada. 8Centre antipoison du Québec, Department of Medicine, McGill University, Department of Emergency Medicine, McGill University Health Centre, Montreal, QC, Canada. 9Division of Medical Toxicology, Department of Emergency Medicine, Carolinas Medical Center, Charlotte, NC. 10Quebec Poison Centre, Department of Emergency Medicine, McGill University Health Centre, Montreal, QC, Canada. 11Department of Emergency Medicine, Denver Health and Hospital Authority, University of Colorado, Boulder, CO. 12Ontario Poison Centre, Sunnybrook Health Sciences Centre, Departments of Medicine and Pediatrics, University of Toronto, Toronto, ON, Canada. 13Kingston General Hospital, Queens' University, Kingston, ON, Canada. 14Institute of Environmental & Occupational Health Sciences, School of Medicine, National Yang-Ming University, Taipei, Taiwan. 15Division of Clinical Toxicology & Occupational Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 16Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, and Interdepartmental Division of Critical Care, University of Toronto, Toronto, ON, Canada. 17Department of Paediatrics, Physiology and Pharmacology and Medicine, Western University, London, ON, Canada. 18Department of Medical and Toxicological Critical Care, Lariboisière Hospital, INSERM U1144, Paris-Diderot University, Paris, France.
This study provides a stepwise management approach for adults with calcium channel blocker poisoning, outlining recommended treatments from observation to advanced life support. Evidence levels for interventions in calcium channel blocker toxicity were very low.
Area of Science:
- Emergency Medicine
- Medical Toxicology
- Cardiology
Background:
- Calcium channel blocker (CCB) overdose is a life-threatening condition requiring prompt and effective management.
- CCB poisoning can lead to severe cardiovascular complications including hypotension, bradycardia, and cardiogenic shock.
- Existing management strategies for CCB toxicity vary, necessitating evidence-based guidelines.
Framework:
- This guideline was developed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument.
- Evidence summaries, risks, and benefits were synthesized to formulate voting statements.
- Recommendations are presented in a stepwise approach based on patient presentation and treatment response.
Implementation:
- For asymptomatic patients, observation and decontamination are recommended.
- First-line therapies include intravenous calcium, high-dose insulin, and vasopressors (norepinephrine/epinephrine).
- Second-line and advanced therapies include lipid emulsion, pacemakers, and extracorporeal membrane oxygenation (ECMO) for refractory cases.
Implications:
- These recommendations provide a structured approach to managing CCB poisoning in adults.
- The guidelines aim to optimize patient outcomes by standardizing treatment protocols.
- Further research is needed to strengthen the evidence base for CCB toxicity interventions.
Related Concept Videos
Pharmaceutical Poisoning: Treatment Strategies
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Acute Coronary Syndrome IV: Interprofessional Care
Cardiopulmonary Resuscitation IV: Pharmacological Management
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...


